SERUM LEVELS OF FIBROBLAST GROWTH FACTOR-23, OSTEOPROTEGERIN, AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B LIGAND IN PATIENTS WITH PROLACTINOMA

2017 ◽  
Vol 23 (3) ◽  
pp. 266-370
Author(s):  
Muyesser Sayki Arslan ◽  
Mustafa Sahin ◽  
Melia Karakose ◽  
Esra Tutal ◽  
Oya Topaloglu ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Nuclear Factor Kappa B ◽  
Fibroblast Growth Factor 23 ◽  
Serum Levels ◽  
Nuclear Factor ◽  
Fibroblast Growth ◽  
Nuclear Factor Kappa ◽  
Receptor Activator

Cardiac hypertrophy elevates serum levels of fibroblast growth factor 23

2018 ◽  
Vol 94 (1) ◽  
pp. 60-71 ◽  
Author(s):  
Isao Matsui ◽  
Tatsufumi Oka ◽  
Yasuo Kusunoki ◽  
Daisuke Mori ◽  
Nobuhiro Hashimoto ◽  
...  
Keyword(s):  
Growth Factor ◽  
Cardiac Hypertrophy ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Serum Levels ◽  
Fibroblast Growth

scholarly journals Regulation of serum 1,25(OH)2Vitamin D3 levels by fibroblast growth factor 23 is mediated by FGF receptors 3 and 4

2011 ◽  
Vol 301 (2) ◽  
pp. F371-F377 ◽  
Author(s):  
Jyothsna Gattineni ◽  
Katherine Twombley ◽  
Regina Goetz ◽  
Moosa Mohammadi ◽  
Michel Baum
Keyword(s):  
Vitamin D ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Serum Levels ◽  
Phosphate Transport ◽  
Fibroblast Growth ◽  
Wild Type ◽  
Baseline Serum ◽  
Renal Phosphate Reabsorption

Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone implicated in the pathogenesis of several hypophosphatemic disorders. FGF23 causes hypophosphatemia by decreasing the expression of sodium phosphate cotransporters (NaPi-2a and NaPi-2c) and decreasing serum 1,25(OH)2Vitamin D3 levels. We previously showed that FGFR1 is the predominant receptor for the hypophosphatemic actions of FGF23 by decreasing renal NaPi-2a and 2c expression while the receptors regulating 1,25(OH)2Vitamin D3 levels remained elusive. To determine the FGFRs regulating 1,25(OH)2Vitamin D3 levels, we studied FGFR3−/−FGFR4−/− mice as these mice have shortened life span and are growth retarded similar to FGF23−/− and Klotho−/− mice. Baseline serum 1,25(OH)2Vitamin D3 levels were elevated in the FGFR3−/−FGFR4−/− mice compared with wild-type mice (102.2 ± 14.8 vs. 266.0 ± 34.0 pmol/l; P = 0.001) as were the serum levels of FGF23. Administration of recombinant FGF23 had no effect on serum 1,25(OH)2Vitamin D3 in the FGFR3−/−FGFR4−/− mice (173.4 ± 32.7 vs. 219.7 ± 56.5 pmol/l; vehicle vs. FGF23) while it reduced serum 1,25(OH)2Vitamin D3 levels in wild-type mice. Administration of FGF23 to FGFR3−/−FGFR4−/− mice resulted in a decrease in serum parathyroid hormone (PTH) levels and an increase in serum phosphorus levels mediated by increased renal phosphate reabsorption. These data indicate that FGFR3 and 4 are the receptors that regulate serum 1,25(OH)2Vitamin D3 levels in response to FGF23. In addition, when 1,25(OH)2Vitamin D3 levels are not affected by FGF23, as in FGFR3−/−FGFR4−/− mice, a reduction in PTH can override the effects of FGF23 on renal phosphate transport.

Lower soluble Klotho and higher fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation

Cytokine ◽  
2018 ◽  
Vol 111 ◽  
pp. 106-111 ◽  
Author(s):  
Katarzyna Mizia-Stec ◽  
Joanna Wieczorek ◽  
Mateusz Polak ◽  
Maciej T. Wybraniec ◽  
Iwona Woźniak-Skowerska ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Serum Levels ◽  
Fibroblast Growth

scholarly journals P3010Lower soluble Klotho and higher impact fibroblast growth factor 23 serum levels are associated with episodes of atrial fibrillation

2017 ◽  
Vol 38 (suppl_1) ◽  
Author(s):  
K. Mizia-Stec ◽  
J. Wieczorek ◽  
A.M. Wnuk-Wojnar ◽  
I. Wozniak-Skowerska ◽  
M. Wybraniec ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Fibroblast Growth Factor 23 ◽  
Serum Levels ◽  
Fibroblast Growth

scholarly journals Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism

2011 ◽  
Vol 34 (4) ◽  
pp. 232 ◽  
Author(s):  
Carmen E Pepene ◽  
Nicolae Crişan ◽  
Ioan Coman
Keyword(s):  
Nuclear Factor Kappa B ◽  
Late Onset ◽  
Elevated Serum ◽  
Serum Levels ◽  
Sex Hormone Binding Globulin ◽  
Male Hypogonadism ◽  
Nuclear Factor ◽  
Nuclear Factor Kappa ◽  
Receptor Activator ◽  
Late Onset Hypogonadism

Purpose: Studies that analyze the levels of osteoprotegerin (OPG) or receptor activator of nuclear factor kappa B ligand (RANKL) in hypogonadal men, the majority of whom have prostate cancer or are undergoing androgen-deprivation therapy, are few and inconclusive. Methods: 81 men aged 69.3 ± 0.8 years (39 men with late-onset hypogonadism and 42 age-matched controls) were recruited. Serum levels of OPG, total soluble RANKL (sRANKL), total and free testosterone (FT), estradiol (E2), sex hormone-binding globulin (SHBG), follicle-stimulating hormone, luteinizing hormone (LH), prolactin, bone-specific alkaline phosphatase (BAP) and β-Cross Laps were assessed. Results: Compared with controls, both OPG (p = 0.023) and sRANKL (p = 0.010) serum levels were increased in men with late-onset hypogonadism; however, when expressed as a ratio, sRANKL/OPG, the two groups were not significantly different. Simple and age-adjusted analyses showed that OPG was inversely related to FT and positively related to SHBG, E2 and BAP. In the patient population, LH demonstrated statistically significant correlations with both OPG (r = 0.274, p = 0.013) and sRANKL (r = 0.276, p = 0.018). Multiple regression analysis retained age, SHBG, E2 and BAP as independent predictors of OPG, explaining 27.71% of serum OPG variability. Conclusions: Late-onset hypogonadism is associated with enhanced RANKL activity. Increased bone turnover-related OPG levels may act as a coupling factor between bone resorption and formation. The results suggest anti-RANKL-agents as therapeutic tools in osteoporotic men with late-onset hypogonadism.

Sign in / Sign up

Export Citation Format

Share Document